Introduction

Dupilumab is a treatment option newly licensed for adolescents with moderate to severe atopic dermatitis (AD). It reduces type 2 inflammation by blocking the shared receptor subunit for IL-4/-13. Dupilumab affects three disease mechanisms in atopic dermatitis: the skin barrier, the Th2-cell differentiation and the class switch to IgE. This report is based on a systematic literature search of the PubMed Database.

Areas covered

Dupilumab showed promising results in improving AD signs, symptoms and quality of life in adolescents with moderate to severe AD. The safety profile of dupilumab in adolescents with moderate to severe AD closely resembled the known safety profile of dupilumab in adults with moderate to severe AD. Injection-site reactions and conjunctivitis were the relevant side-effects. Skin infections were less frequently observed compared to placebo.

Expert commentary

Dupilumab was approved by the Food and Drug Administration in March 2019 and by the European Medicines Agency in August 2019 for the treatment of adolescents with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical therapies or when those therapies are not advisable. Since it is the first licensed drug it will likely become the reference drug for adolescents with moderate to severe AD.

中文翻译：

---

Dupilumab 用于治疗青少年特应性皮炎。

介绍

Dupilumab 是一种新获准用于中重度特应性皮炎 (AD) 青少年的治疗选择。它通过阻断 IL-4/-13 的共享受体亚基来减少 2 型炎症。Dupilumab 影响特应性皮炎的三种疾病机制：皮肤屏障、Th2 细胞分化和向 IgE 的类别转换。本报告基于对 PubMed 数据库的系统文献检索。

覆盖区域

Dupilumab 在改善患有中度至重度 AD 的青少年的 AD 体征、症状和生活质量方面显示出有希望的结果。dupilumab 在中重度 AD 青少年中的安全性与 dupilumab 在中重度 AD 成人中的已知安全性非常相似。注射部位反应和结膜炎是相关的副作用。与安慰剂相比，观察到皮肤感染的频率较低。

专家评论

Dupilumab 于 2019 年 3 月和欧洲药品管理局分别于 2019 年 3 月和 2019 年 8 月获得批准，用于治疗患有中度至重度特应性皮炎的青少年，这些患者的疾病无法通过局部治疗得到充分控制或不建议使用这些治疗。由于它是第一个获得许可的药物，它很可能成为中度至重度 AD 青少年的参考药物。